Cardinal Health (NYSE:CAH) Price Target Raised to $280.00

Cardinal Health (NYSE:CAH) had its price objective boosted by equities researchers at Citigroup from $265.00 to $280.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price would suggest a potential upside of 18.01% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Mizuho upped their price objective on shares of Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday. William Blair began coverage on shares of Cardinal Health in a research report on Tuesday, April 28th. They set an “outperform” rating for the company. Evercore reissued an “outperform” rating and issued a $270.00 price target on shares of Cardinal Health in a report on Wednesday. Leerink Partners set a $292.00 price objective on shares of Cardinal Health in a research note on Tuesday. Finally, TD Cowen boosted their target price on Cardinal Health from $255.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Fifteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Cardinal Health presently has a consensus rating of “Moderate Buy” and an average price target of $261.47.

Cardinal Health Stock Performance

Shares of CAH traded down $3.00 during mid-day trading on Wednesday, hitting $237.26. 798,941 shares of the company’s stock were exchanged, compared to its average volume of 2,033,412. The company has a market cap of $55.57 billion, a price-to-earnings ratio of 36.28, a P/E/G ratio of 1.16 and a beta of 0.49. Cardinal Health has a fifty-two week low of $145.47 and a fifty-two week high of $258.30. The stock’s 50-day moving average is $228.37 and its 200-day moving average is $216.66.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities research analysts anticipate that Cardinal Health will post 10.77 EPS for the current year.

Hedge Funds Weigh In On Cardinal Health

Several hedge funds and other institutional investors have recently bought and sold shares of CAH. Investors Research Corp acquired a new position in shares of Cardinal Health in the second quarter worth about $29,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cardinal Health in the fourth quarter worth $26,000. Allied Private Wealth LLC acquired a new position in shares of Cardinal Health in the 2nd quarter valued at about $30,000. Bank of Jackson Hole Trust acquired a new position in Cardinal Health in the fourth quarter valued at approximately $27,000. Finally, Indiana Trust & Investment Management Co acquired a new position in Cardinal Health during the 1st quarter valued at approximately $29,000. 87.17% of the stock is owned by institutional investors and hedge funds.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Fiscal 2027 outlook exceeded expectations. Cardinal Health forecast adjusted EPS of $12.40-$12.60, representing 13%-15% growth and above the roughly $12.05 analyst consensus. Management expects normalized pharmaceutical demand, specialty pharmaceuticals, At-Home solutions and productivity initiatives to support growth. Cardinal Health forecasts full-year profit above estimates
• Positive Sentiment: Fourth-quarter adjusted EPS beat estimates. Adjusted earnings rose to $2.91 per share from $2.08 a year earlier, exceeding expectations of $2.42. Profit benefited from strong specialty-drug demand and nearly doubled Medtech earnings, although a $0.31-per-share tariff refund also contributed. CAH Q4 Earnings Beat on Pharma Strength
• Positive Sentiment: Share repurchases were expanded by $5 billion. Cardinal completed $1.4 billion of buybacks in fiscal 2026 and authorized an additional $5 billion, potentially providing meaningful support to per-share earnings and the stock. Analysts at Wells Fargo and Robert W. Baird also raised their price targets to $277 and $274, respectively. Cardinal Health Analysts Increase Their Forecasts
• Neutral Sentiment: Cardinal Health declared a quarterly dividend of $0.5158 per share, payable October 15 to shareholders of record October 1. The dividend reinforces the company’s capital-return strategy but carries a relatively modest yield. Cardinal Health Board Approves Quarterly Dividend
• Negative Sentiment: Fourth-quarter revenue increased 6% year over year to $63.67 billion, but missed the approximately $65.1 billion consensus estimate. Investors may also discount the earnings beat because part of the improvement came from a one-time tariff refund rather than recurring operations. Cardinal Health Q4 Earnings Results

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.